EuropaWire2d
Basilea Secures USD 268 Million Agreement with BARDA to Develop Novel Antifungal and Antibacterial Treatments
Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority ...
Basilea Enters Into Agreement With BARDA To Develop Novel Antifungals And Antibacterials And Receives Initial Funding
Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix a ...
finanzen3d
Press Release: Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix and BAL2062 -- ...
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
Expands available market to include over 200 children’s hospitals in the United StatesLEXINGTON, Mass., Sept. 16, 2024 (GLOBE ...
University of Manchester5d
Ignore antifungal resistance in fungal disease at your peril, warn top scientists
Without immediate action, humanity will face a potentially disastrous escalation in resistance in fungal disease, a renowned ...